Compare Abbott Laboratories (ABT) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Peloton Interactive Inc — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while Peloton Interactive Inc trades at $5.78 (market cap $2.52B). The key difference: Abbott Laboratories is far larger — about 66.2× Peloton Interactive Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Peloton Interactive Inc pays none. Which is the better fit depends on your goals.
| ABT | PTON | |
|---|---|---|
Market Cap | $166.94B | $2.52B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $9.00 |
52-Week Low | $82.57 | $3.71 |
Enterprise Value | $193.69B | $3.12B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Peloton (PTON) trades at $5.82, up 1.22% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals, with operating cash flow turning positive to $333 million in 2025 and net losses narrowing significantly. Recent news highlights a potential turnaround, including inclusion in the S&P SmallCap 600 index and the appointment of a new CFO.
The outlook is cautiously optimistic as Peloton aims for profitability, but risks remain from high debt and revenue declines. Analyst consensus is a Buy with a $7.50 price target, suggesting 29% upside, though execution on growth initiatives is critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
